About the Product

Description


Botans 62.5 Tablet contains Bosentan (62.5 mg), a potent endothelin receptor antagonist (ERA) used to manage pulmonary arterial hypertension (PAH). It works by relaxing blood vessels in the lungs, reducing high blood pressure, and improving oxygen flow, which helps enhance physical activity and overall quality of life for PAH patients.

This medication is particularly effective in slowing disease progression, improving exercise capacity, and minimizing symptoms like shortness of breath and fatigue in individuals suffering from PAH.

Mechanism of Action:

Bosentan blocks endothelin-1 receptors (ET-1), preventing blood vessel constriction and promoting relaxation. This process reduces pressure in the pulmonary arteries, easing the heart’s workload and improving circulation.

Common side effects may include headache, flushing, swelling of legs/ankles, nasal congestion, low blood pressure, and liver enzyme abnormalities. Regular liver function monitoring is recommended.

Used for the treatment of pulmonary arterial hypertension (PAH) to improve exercise tolerance and delay disease progression.

This medication should be taken only under a doctor's supervision. It is not recommended during pregnancy and may require regular liver function and blood tests. Women of childbearing potential should use effective contraception while taking this medication.

Store in a cool, dry place, away from direct sunlight and moisture. Keep out of reach of children.Store in a cool, dry place, away from direct sunlight and moisture. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Frequently Asked Questions

What are the business opportunities for Bosentan 62.5 mg Tablet in the PCD pharma franchise market?

Bosentan 62.5 mg Tablet has strong demand in the specialty cardiology and pulmonology (PAH) segment, making it a high-value product for medical distributors, wholesalers, and pharma franchise partners focusing on critical-care and chronic disease portfolios.

Why should medical distributors include Bosentan in their product range?

Medical distributors and agencies can benefit from consistent demand for management of pulmonary arterial hypertension (PAH), a serious chronic condition requiring long-term therapy. Bosentan is an endothelin receptor antagonist that helps relax pulmonary blood vessels It improves blood flow and reduces pulmonary artery pressure This makes it a specialty hospital-based molecule with stable, long-term prescriptions.

Does Cafoli LifeCare Pvt Ltd offer PCD pharma franchise opportunities for this product?

Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for Bosentan 62.5 mg Tablet with promotional support, monopoly rights, quality packaging, and competitive pricing for distributors and wholesalers.

What benefits do wholesalers get by partnering for this product?

Wholesalers and medical agencies benefit from hospital and specialist prescriptions, long-term chronic therapy demand, niche high-value segment, institutional supply opportunities, and good margins in super-specialty cardiovascular/pulmonary medicines.

How can I become a distributor or franchise partner for Bosentan 62.5 mg Tablet?

Interested distributors, stockists, and wholesalers can contact Cafoli LifeCare Pvt Ltd to discuss pricing, territory rights, and distribution opportunities.